睿知中国医院研究地图
候选清单

邀请入组淋巴瘤III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由南昌大学第二附属医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方南昌大学第二附属医院Second Affiliated Hospital of Nanchang University南昌医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07348575,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. EBER+ or peripheral blood EBV-DNA of pathological specimen was greater than 103copy/ml;

    入选标准第 3 条

  3. Neutrophils < 1.5 x 109/L;

    排除标准第 9 条

    Platelet < 75 x 109/L;

    排除标准第 10 条

    ALT or AST were 2 times higher than the upper limit of normal, AKP and bilirubin were 1.5 times higher than the upper limit of normal;

    排除标准第 11 条

    creatinine levels higher than 1.5 times the upper limit of normal;

    排除标准第 12 条

  4. Known human immunodeficiency virus (HIV) infection, or active hepatitis B or C virus infection (polymerase chain Reaction [PCR] showed positive results). If the HbsAg test result is positive, HBV DNA test should be performed, if the HBV DNA<103IU/ml, can be enrolled. If HBsAg test results are negative, but HBcAb test is positive (regardless of HBsAb status), HBV DNA test is also required, and HBV DNA<103 IU/ml can be enrolled. If the patient's HCV antibody is positive, the HCV RNA is detected by PCR. If positive, the exclusion criteria are met.

    排除标准第 15 条

  5. Pregnant or lactating women;

    排除标准第 14 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);既往治疗;日常活动能力;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07348575,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Initial treatment of diffuse large B-cell lymphoma (DLBCL) confirmed by tumor histopathology with at least one lesion on either axis More than 1.5 cm, sufficient specimens for second-generation sequencing or single-cell sequencing;
  2. Age > 18 years old, < 80 years old, gender unlimited;
  3. EBER+ or peripheral blood EBV-DNA of pathological specimen was greater than 103copy/ml;
  4. Patients judged by the investigator to have a life expectancy of at least 6 months;
  5. The patient or his legal representative must provide written informed consent prior to any research special examination or procedure.
  6. Signed written informed consent before screening.

排除标准:Exclusion Criteria:

  1. Have previously received systemic or local treatment including chemotherapy;
  2. Previously received autologous stem cell transplantation;
  3. Previous history of other malignant tumors, except skin basal cell carcinoma and cervical carcinoma in situ;
  4. Accompanied by uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases and serious infectious diseases;
  5. Lymphoma involves the central nervous system;
  6. Primary mediastinal large B-cell lymphoma;
  7. Left ventricular ejection fraction < 50%;
  8. Laboratory test values at the time of screening: (unless due to lymphoma);
  9. Neutrophils < 1.5 x 109/L;
  10. Platelet < 75 x 109/L;
  11. ALT or AST were 2 times higher than the upper limit of normal, AKP and bilirubin were 1.5 times higher than the upper limit of normal;
  12. creatinine levels higher than 1.5 times the upper limit of normal;
  13. Patients with mental illness or other patients known or suspected to be unable to fully comply with the study protocol;
  14. Pregnant or lactating women;
  15. Known human immunodeficiency virus (HIV) infection, or active hepatitis B or C virus infection (polymerase chain Reaction [PCR] showed positive results). If the HbsAg test result is positive, HBV DNA test should be performed, if the HBV DNA<103IU/ml, can be enrolled. If HBsAg test results are negative, but HBcAb test is positive (regardless of HBsAb status), HBV DNA test is also required, and HBV DNA<103 IU/ml can be enrolled. If the patient's HCV antibody is positive, the HCV RNA is detected by PCR. If positive, the exclusion criteria are met.
  16. Other concurrent and uncontrolled medical conditions that the investigator believes will affect the patient's participation in the study.

引自 ClinicalTrials.gov, NCT07348575, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07348575,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07348575